The effects of valbenazine on tardive dyskinesia in older and younger patients

OBJECTIVE: To evaluate the effects of once‐daily valbenazine (40 or 80 mg/d) in older and younger adults with tardive dyskinesia (TD). METHODS: Data were pooled from three 6‐week, randomized, double‐blind, placebo‐controlled (DBPC) studies (KINECT [NCT01688037], KINECT 2 [NCT01733121], and KINECT 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajatovic, Martha, Alexopoulos, George S., Burke, Joshua, Farahmand, Khodayar, Siegert, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916547/
https://www.ncbi.nlm.nih.gov/pubmed/31617235
http://dx.doi.org/10.1002/gps.5218
Descripción
Sumario:OBJECTIVE: To evaluate the effects of once‐daily valbenazine (40 or 80 mg/d) in older and younger adults with tardive dyskinesia (TD). METHODS: Data were pooled from three 6‐week, randomized, double‐blind, placebo‐controlled (DBPC) studies (KINECT [NCT01688037], KINECT 2 [NCT01733121], and KINECT 3 [NCT02274558]) and two long‐term studies (KINECT 3 extension and KINECT 4 [NCT02405091]). Outcomes analyzed in older and younger participants (55 years or older and younger than 55 years, respectively) included Abnormal Involuntary Movement Scale (AIMS) response (threshold of greater than or equal to 50% improvement from baseline in total score [items 1 to 7]) and Clinical Global Impression of Change—Tardive Dyskinesia (CGI‐TD) response (score 2 or less [“very much improved” or “much improved”]). Safety assessments included treatment‐emergent adverse events (TEAEs). RESULTS: At week 6 (end of DBPC treatment), the percentage of participants who met the AIMS response threshold was higher with valbenazine versus placebo in both subgroups: 55 years or older (80 mg/d, 39.7% [P < .001]; 40 mg/d, 28.6% [P < .01]; placebo, 9.7%); younger than 55 years (80 mg/d, 39.5% [P < .001]; 40 mg/d, 20.0% [P > .05]; placebo, 10.8%). The percentage of participants with CGI‐TD response was also higher with valbenazine versus placebo: 55 years or older (80 mg/d, 41.3% [P < .01]; 40 mg/d, 30.2% [P > .05]; placebo, 19.4%); younger than 55 years (80 mg/d, 39.5% [P < .05]; 40 mg/d, 35.3% [P < .05]; placebo, 18.5%). Responses at week 48 (end of long‐term treatment, combined doses) were as follows: 55 years or older (AIMS, 70.7%; CGI‐TD, 82.8%); younger than 55 years (AIMS, 58.7%; CGI‐TD, 72.3%). No significant differences between older and younger subgroups were found for AIMS or CGI‐TD response. No new safety signals or TEAEs of clinical concern were found in older participants who received long‐term treatment. CONCLUSIONS: Valbenazine improved TD and was generally well tolerated in older and younger adults.

Ejemplares similares